Pharmacoeconomic evaluation of antidepressants: A critical appraisal of methods

PharmacoEconomics

Volumn 23, Issue 6, 2005, Pages 595-606

  Iqbal, Sheikh Usman ^a   Prashker, Mark ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEPRESSION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; MODEL; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOTHERAPY; QUALITY CONTROL; QUALITY OF LIFE; RELIABILITY; RETROSPECTIVE STUDY; REVIEW; STANDARD; VALIDATION PROCESS; WELLBEING;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSION; ECONOMICS, PHARMACEUTICAL; HUMANS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 22244489727     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523060-00006     Document Type: Review

References (51)

1. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for economic evaluation of health care programmes. New York: Oxford University Press Inc., 1997
2. Motheral B, Brooks J, Clark MA, et al. A checklist for retro-spective database studies: report of the ISPOR Task Force on Retrospective Database. Value Health 2003; 6: 90-7
3. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71-9
4. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715-30
5. Simon GE, Fishman P. Cost implications of initial antidepres-sant selection in primary care. Pharmacoeconomics 1998; 13: 61-70
6. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38: 97-111
7. Melton ST, Kirkwood CK, Farrar TW, et al. Economic evalua-tion of paroxetine and imipramine in depressed outpatients. Psychopharmacol Bull 1997; 33: 93-100
8. Bhaumik S, Branfold D, Dugginala C, et al. A naturalistic study of the use of antidepressants in adults with learning disabilities and affective disorders. Leicester: Frith Hospital, 1995
9. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 735-1739
10. Crown WH. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. Acta Psychiatr Scand 2000; 101 Suppl. 403: 62-6
11. Lader M. Current trends in drugs for depression. Update 1996;52: 149-53
12. Antonuccio DO, Danton WG. Psychotherapy versus medication for depression: challenging the conventional wisdom with data. Prof Psychol Res Pr 1995; 26: 574-85
13. Stewart A. Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 1998; 48: 125-33
14. Vonkorff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203
15. Katzeinick DJ, Koback KA, Jefferson JW, et al. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996; 31: 374-88
16. Rosholm JU, Gram LF, Isacsson G, et al. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 1997; 52: 205-9
17. Sclar DA, Skaer TL, Robison LM, et al. Evidence based algorithm for antidepressant pharmacotherapy. JAMA (Sea) 1997; 13: 33-40
18. Katon W, Von Korff M, Lin E. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67-76
19. Bruce EL, Haiden AH, Carol T, et al. The evolution of quality manmanagement in state Medicaid agencies: a national survey of states with comprehensive managed care programs. Jt Comm J Qual Improv 2002; 28: 426-36
20. Lin EH, Von KM, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33: 67-4
21. Einarson TR, Arkian S, Sweeney S, et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136-53
22. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
23. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997; 12: 286-96
24. Doyle J, Casciano J, Arkinian S, et al. The health economic impact of antidepressant usage from a payer's perspective: a multinational study. Int J Clin Pract 2001; 55: 292-9
25. Lapierre Y, Bentkover J, Schainbum S, et al. Direct costs of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370-7
26. Nutjen MJC, Hardens M, Soutre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8: 159-68
27. New evidence-based treatments for depression. Proceedings of the Magellan Behavioral Health 2001 Clinical Medical Retreat. Managed Care 2001; 10 (Spec Suppl): 1-25
28. Johnson DA. Treatment compliance in general practice. Acta Psychiatr Scand 1981; 63 Suppl. 209: 447-53
29. Judith RL, Richard GF, Herbert CS, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645-51
30. Freemantle N, House A, Song F. Prescribing selective serotonin reuptake inhibitors as a strategy for prevention of suicide. BMJ 1994; 309: 249-53
31. Therese MC, Crismon ML, Daniel JS. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother 1999; 33: 364-72
32. Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions. Depress Anxiety 1998; 8 Suppl. 1: 121-7
33. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996; 306: 683-7
34. Agency for Health Care Policy Research (AHCPR) Depression Guideline Panel. Treatment of Major Depression (Depression in primary care 2) Clinical Practice Guideline 5. Rockville (MD): US Department of Health and Human Services, Public health Service, AHCPR, 1993. AHCPR Publication 93-0550
35. John AH, Carol AR. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Pharmacoeconomics 1997; 11: 515-37
36. Anderson UA, Andersen M, Rosholm JU, et al. Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 2001; 104: 458-65
37. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215-8
38. Hale AS. The importance of accidents in evaluating the cost of SSRIs: a review. Int Clin Psychopharmacol 1994; 9: 195-201
39. Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand 1998; 97: 241-52
40. Minshall ME, Kody MC, Mosbacher F. Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research. Med Care 1999; 37: 12-9
41. Skaer TL, Sclar DA, Robison LM, et al. The need for an iterative process for assessing economic outcomes associated with SSRIs. Pharmacoeconomics 2000; 18: 205-14
42. Curran HV, Sakulsripong M, Lader M. Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology (Berl) 1988; 95: 520-7
43. Peselow ED, Corwin J, Fieve RR. Disappearance of memory deficits in outpatient depressives responding to imipramine. J Affect Disord 1991; 21: 173-83
44. Jacobson F. Fluoxetine induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119-22
45. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
46. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96
47. Matthew H, Glyn L, Charles N. Putting trials on trial-the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health 1997; 51: 354-8
48. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 2: 32-5
49. Conti DJ, Burton WN. Economic impact of depression in a workplace [abstract]. J Occup Environ Med 1994; 36: 983-8
50. Rand Corporation. The course of depression in adult outpatients: results from the medical outcomes study. Arch Gen Psychiatry 1992; 49: 788-94
51. National Mental Health Association and Employee Assistance Professionals Association. Depression: its effects on the work force. Exchange 1996; 26: 5